Wolverine + the GH stack
Two popular stacks run together, and the overlap between them is larger than it looks.
People heal an injury with BPC-157 and TB-500, then add CJC-1295 and ipamorelin to build while they recover. Four compounds, sold as two separate stacks, and nobody has tested either half alongside the other. The skin version swaps GHK-Cu in for the healing pair and is covered below.
Heal the injury, and do not lose ground while it heals.
The situation is specific. Somebody is hurt, training is limited, and they are watching progress slip away while the tissue repairs. Wolverine is aimed at the repair. The GH pairing is aimed at the ground being lost.
Both stacks are already popular on their own, which is most of why they end up together. Somebody who has read about one tends to read about the other, and adding the second is a small step from there.
Sleep is the other reason. The GH pairing's most consistently reported effect is deeper sleep, and sleeping badly is common when an injury is painful.
Four benefits, and how well each one holds up.
The only proven row is a number in a blood test. Everything the four compounds are taken for sits above it.
Three questions, answered before anything else.
Two stacks, and one shared destination.
The case for combining them is that they do separate jobs. Repair on one side, growth on the other. Follow the mechanisms and they converge sooner than expected.
It matters for a practical reason. Anyone deciding what to drop when money is tight has been told these are two separate investments. On the repair side specifically, they are closer to two bets on the same thing.
The part that does not overlap is muscle. Holding lean mass while training is limited is a growth hormone job and the healing pair has nothing to say about it. That is the honest argument for adding the second stack, and no trial has tested it in an injured person.
Four compounds, and one randomised trial between them.
CJC-1295 is the only one here with a proper trial in healthy adults. Teichman 2006 found growth hormone rising two to tenfold for six days after one injection, with IGF-1 up to threefold for two weeks.[1] It measured no clinical outcome.
Ipamorelin has been tested twice in patients, in two Phase 2 trials enrolling 437 people between them for recovery of bowel function after surgery. Neither found a significant benefit.[2] That record is covered in full here.
BPC-157 reached a Phase 2 trial for a bowel condition and the results were never published. TB-500 has no human efficacy trial at all, and the eye-drop trials people cite belong to thymosin beta-4, a longer molecule. The Wolverine page covers that discrepancy.
So the strongest evidence in this stack is a hormone measurement, and the most rigorous test anyone ran on any of the four came back negative.
Four vials, two blends, or one that hides its contents.
Nobody sells this exact four-compound combination premixed. There are three routes to it, and they differ more in what you know than in what you pay.
The bottom row needs explaining. One vendor sells a four-compound vial at $69.99 containing tesamorelin, ipamorelin, CJC-1295 and TB-500.[5] It is the cheapest route and it is not this stack.
It publishes no amounts for any of the four, and it contains both tesamorelin and CJC-1295, which are both GHRH analogs acting on the same receptor. That is one mechanism paid for twice in a single vial, and the three-compound page covers why that matters. It also swaps out BPC-157 entirely, so the healing half is TB-500 alone.
Buying four vials costs $82.31, tells you exactly what is in each, and lets you stop any one compound without losing the rest.
Swap the healing pair for GHK-Cu.
The other common version of this idea drops BPC-157 and TB-500 and adds GHK-Cu instead, pairing skin quality with the growth hormone stack. It costs $61.04 as three separate vials, or $66.49 buying the GH pair premixed.[5]
The overlap problem is the same and arguably sharper. GHK-Cu signals collagen production. Raising IGF-1 promotes collagen synthesis. Both compounds are bought for the same protein.
GHK-Cu also brings the route problem that runs through every page it appears on. Its human evidence is the strongest in the skin category and all of it comes from creams put on the skin, while this stack injects it. That is covered here.
One thing improves. Dropping TB-500 removes the WADA violation, so unlike the four-compound version this one is not automatically disqualifying for a tested athlete. GHK-Cu, CJC-1295 and ipamorelin are all unapproved, and none is on the prohibited list.
All four unapproved, and one of them banned in sport.
None of the four has an approved label in any country. BPC-157, CJC-1295 and ipamorelin all sit in Category 2 on the FDA 503A list, the register of ingredients compounding pharmacies may work with, which is the tier meaning not allowed.
TB-500 was moved into Category 2 in February 2026, and it is also banned in and out of competition under section S2 of the 2026 WADA list.
A stack takes on the strictest status of anything inside it. Any tested athlete taking the four-compound version has committed a doping violation regardless of what the other three do.
Anyone taking this has a specific reason to have IGF-1 checked. Raising it is the one documented effect of the GH half, and the long-term consequences of holding it high are not established. That is a conversation for a doctor.
What people ask about this stack
Is it worth running Wolverine and the GH stack together?
Nobody has tested either pair, let alone both together. The honest argument for adding the growth hormone stack is muscle, since holding lean mass while training is limited is something BPC-157 and TB-500 have nothing to say about. On repair specifically the two halves overlap, because growth hormone raises IGF-1 and IGF-1 drives collagen production, which is the same job the healing pair is bought for.
Do the four compounds overlap?
On tissue repair, yes. BPC-157 is linked to growing blood vessels into damaged tissue and to the cells that lay down collagen. Raising growth hormone promotes collagen synthesis through IGF-1. Two routes to one outcome is a legitimate strategy, but the usual argument for combining stacks, that each covers what the other misses, is weaker here than it sounds.
What does it cost?
Four separate vials come to $82.31 at the cheapest in-stock listings, and that is the only route where every amount is stated. Buying Wolverine and the CJC-1295 pairing as two premixed blends costs $96.00. A four-compound blend exists at $69.99 but contains different compounds and publishes no amounts.
Is there a premixed version?
Not of this exact combination. One vendor sells a four-compound vial at $69.99 containing tesamorelin, ipamorelin, CJC-1295 and TB-500. It states no amounts for any of them and drops BPC-157 entirely. It also contains two GHRH analogs acting on the same receptor, which is one mechanism paid for twice in a single vial.
What about CJC-1295 and ipamorelin with GHK-Cu instead?
The GHK-Cu version pairs skin quality with the growth hormone stack and costs $61.04 as three vials. The overlap problem is sharper, since GHK-Cu signals collagen production and raising IGF-1 promotes collagen synthesis, so both are bought for the same protein. It does remove the WADA problem, because dropping TB-500 leaves nothing on the prohibited list.
Can athletes take this?
Not the four-compound version. TB-500 is banned in and out of competition under section S2 of the 2026 WADA list, and a stack takes on the strictest status of anything inside it. The GHK-Cu version has no banned compound in it. Compare against the other stacks.
What this page is built on
- 01Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006. PMID 16352683. 65 healthy adults, GH up 2 to 10-fold sustained 6 days, IGF-1 up 1.5 to 3-fold for up to 14 days, no clinical outcome measured.
- 02Ipamorelin Phase 2 trial record, both run by Helsinn Therapeutics for postoperative ileus. NCT00672074, 117 patients, completed December 2009, outcome recorded as negative. NCT01280344, 320 patients following bowel resection, completed May 2014, no significant differences in measurable motility against placebo.
- 03IGF-1's role in collagen synthesis and skeletal muscle protein turnover, and the description of BPC-157's link to angiogenesis and fibroblast activity.
- 04TB-500's position on the FDA 503A list following the February 2026 reclassification, and its listing under section S2 of the 2026 WADA prohibited list, banned in and out of competition.
- 05Peptide Decoding vendor pricing data, 16 September 2026. Lowest in-stock single-compound listings: BPC-157 $19.19, TB-500 $21.57, CJC-1295 no DAC $23.99, ipamorelin $17.56, GHK-Cu $19.49. Wolverine blend from $49.00, CJC-1295 plus ipamorelin blend from $47.00. A four-compound vial from Evolve BioPep at $69.99 listing tesamorelin, ipamorelin, CJC-1295 and TB-500 with no amounts stated for any of them.